NCT03449758View on ClinicalTrials.gov

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

SARILUMAB

Pharmaceutical form:Solution for injection in pre-filled syringe Route of administration: Subcutaneous

DRUG

Azathioprine

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Chloroquine

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Hydroxychloroquine

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Leflunomide

Pharmaceutical form:Tablet Route of administration: Oral

DRUG

Methotrexate

Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular

DRUG

Sulfasalazine

Pharmaceutical form:Tablet Route of administration: Oral

Trial Locations (33)

14033

Investigational Site Number 250014, Caen

25030

Investigational Site Number 250006, Besançon

31200

Investigational Site Number 250022, Toulouse

33076

Investigational Site Number 250016, Bordeaux

34295

Investigational Site Number 250029, Montpellier

35022

Investigational Site Number 250017, Rennes

37000

Investigational Site Number 250003, Tours

38434

Investigational Site Number 250009, Échirolles

42055

Investigational Site Number 250001, Saint-Etienne

44035

Investigational Site Number 250025, Nantes

46005

Investigational Site Number 250032, Cahors

49325

Investigational Site Number 250013, Cholet

59037

Investigational Site Number 250004, Lille

63003

Investigational Site Number 250002, Clermont-Ferrand

67098

Investigational Site Number 250034, Strasbourg

69495

Investigational Site Number 250021, Lyon

72037

Investigational Site Number 250024, Le Mans

75012

Investigational Site Number 250010, Paris

75013

Investigational Site Number 250011, Paris

75014

Investigational Site Number 250015, Paris

75015

Investigational Site Number 250028, Paris

75475

Investigational Site Number 250020, Paris

76000

Investigational Site Number 250008, Rouen

85025

Investigational Site Number 250005, La Roche-sur-Yon

86021

Investigational Site Number 250031, Poitiers

87000

Investigational Site Number 250012, Limoges

93000

Investigational Site Number 250027, Bobigny

95300

Investigational Site Number 250023, Pontoise

Unknown

Investigational Site Number 250007, Argenteuil

Investigational Site Number 250018, Montivilliers

Investigational Site Number 250033, Paris

06414

Investigational Site Number 250019, Cannes

06001

Investigational Site Number 250026, Nice

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY